II expansion itself. To provide the kinetics Topoisomerase of leukemia To determine chemistry, we analyzed the peripheral blood at the time of administration according to the number of points plerixafor on day 0 Similar to normal HSC mobilization, mobilization was the peak and total leukocytes of AML blasts in approximately 6 to 12 hours after the administration of plerixafor. We showed a dose-response relationship between plerixafor and mobilization of leukemic Cells mix because of the large-s inter-individual variability of t in the mobilization and the limited number of patients at doses below plerixafor Phase II Phase I studies detect total of 46 patients with plerixafor 0.24 mg / kg / day. In one patient, a single dose of plerixafor was due to grade 2 asymptomatic bradycardia, as m Was possible legally akin to plerixafor. All other patients were new U of the whole course of plerixafor and chemotherapy. Three Todesf Lle occurred may need during the treatment. Two of them were due to sepsis, and the TGF-beta third due to an adverse transfusion reactions occur in the context of febrile neutropenia.
The h Ufigsten h Dermatological serious adverse events w Observed Aurora Kinase during the study years, including 3 4 of fever and infections of the Grade 3 5 Table Acomprehensive treatment side effects, regardless of the assignment is in ergs Complementary given in Table 1. For patients who achieved CR or CRi, neutrophil transplantation occurred at a median 28 days after the start of chemotherapy. For those who achieved CR, Pl occurred ttchenregenerationsrate At a median of 28.5 days. In Phase II, 29 patients were then U is an allogeneic stem cell transplantation, 16 of whom were in the Czech Republic at the time of transplantation. The overall response rate for Phase II was 46%. There was a increased Hte probability favored CR patients with an L Ngeren first CR who received their first salvage treatment. Although trends were a decrease in baseline WBC with age and CR have been identified these covariates is not significantly associated with the reaction. For the cohort of the Phase II, with a median of 19.8 months, median overall survival 8.2 months with a recurrence-free survival of 9.0 months. A year RFS and OS were 37% and amount to 42.9%. The mobilization of leukemic Mix cells, the effect of plerixafor on the mobilization of leukemic Mix cells to determine peripheral blood samples were collected at serial time points after administration of Pimecrolimus plerixafor on day 0. Blasts peripheral blood were identified by both the morphology and by flow cytometry.
Similar to Phase I was to mobilize a total of two and leukemic white blood cells Mix watching blasts after treatment with plerixafor at least 6 hours and remained increased Ht at 24 hours after administration. Again, we observed a significant inter-individual variability of t in the degree of parameters mobilization. We then examined whether the degree ofmobilization with CXCR4 expression on AML blasts correlated, as measured by flow cytometry. A modest correlation between the expression of CXCR4 and Ver Change in the mix leuk Blasts in the peripheral blood between the beginning and 6 hours after plerixafor observed. To determine whether the leukemia has been preconcentrated, purified Preferably mobilized over normal cells, we performed fluorescent in situ hybridization of peripheral blood in a subgroup of patients with informative cytogenetics.